Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. lessened its position in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 1.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,144 shares of the medical instruments supplier’s stock after selling 60 shares during the period. Pittenger & Anderson Inc.’s holdings in Becton, Dickinson and were worth $775,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Icapital Wealth LLC bought a new position in Becton, Dickinson and in the 1st quarter valued at about $31,000. Disciplined Investments LLC acquired a new position in shares of Becton, Dickinson and in the first quarter worth about $32,000. Rosenberg Matthew Hamilton boosted its holdings in shares of Becton, Dickinson and by 61.5% in the first quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 48 shares during the period. Core Alternative Capital boosted its holdings in shares of Becton, Dickinson and by 688.2% in the first quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 117 shares during the period. Finally, McIlrath & Eck LLC boosted its holdings in shares of Becton, Dickinson and by 44.9% in the first quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 44 shares during the period. Institutional investors and hedge funds own 86.74% of the company’s stock.

Becton, Dickinson and Stock Performance

Shares of BDX stock opened at $237.19 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.35 and a quick ratio of 0.90. The stock has a market cap of $67.65 billion, a PE ratio of 40.89, a price-to-earnings-growth ratio of 3.12 and a beta of 0.57. The stock has a 50-day moving average of $252.37 and a 200-day moving average of $253.93. Becton, Dickinson and Company has a one year low of $231.46 and a one year high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last released its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $4.64 billion during the quarter, compared to the consensus estimate of $4.47 billion. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.74 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.

Becton, Dickinson and Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 9th will be given a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.47%. The ex-dividend date is Thursday, September 8th. Becton, Dickinson and’s payout ratio is 60.00%.

Analysts Set New Price Targets

Several brokerages have commented on BDX. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $265.00 to $235.00 in a report on Monday, July 11th. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. The Goldman Sachs Group increased their price target on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Saturday, September 10th. Finally, Wells Fargo & Company upgraded Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price target on the stock in a report on Friday, June 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and has a consensus rating of “Hold” and a consensus target price of $277.63.

Insiders Place Their Bets

In related news, EVP David Hickey sold 475 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.00, for a total value of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares in the company, valued at $882,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Becton, Dickinson and news, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $265.00, for a total value of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares in the company, valued at $882,715. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 9,500 shares of Becton, Dickinson and stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the transaction, the chief executive officer now owns 28,878 shares in the company, valued at approximately $7,656,424.14. The disclosure for this sale can be found here. Insiders have sold 19,160 shares of company stock worth $5,036,751 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Recommended Stories

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.